Log In
BCIQ
Print this Print this
 

temanogrel (formerly APD791)

  Manage Alerts
Collapse Summary General Information
Company Arena Pharmaceuticals Inc.
DescriptionOral inverse agonist of the serotonin (5-HT2A) receptor
Molecular Target Serotonin (5-HT2A) receptor
Mechanism of ActionSerotonin (5-HT2A) receptor inverse agonist
Therapeutic ModalitySmall molecule

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

$2.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

12/03/2012

Undisclosed

0

$2.0M

Get a free BioCentury trial today